DICE Therapeutics, Inc.

18 articles with DICE Therapeutics, Inc.

• DICE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

  3/23/2023

  DICE Therapeutics, Inc. (Nasdaq: DICE) (DICE or the Company) today announced management will participate in a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 30, 2023 at 4:00 p.m. ET.

• DICE Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights

  3/15/2023

  DICE Therapeutics, Inc. (Nasdaq: DICE) (DICE or the Company) today reported financial results for the fourth quarter and full year ended December 31, 2022 and highlighted recent corporate achievements.

• DICE Therapeutics Announces Late-Breaking Presentation at the 2023 American Academy of Dermatology (AAD) Annual Meeting

  3/1/2023

  DICE Therapeutics, Inc. (Nasdaq: DICE) today announced that data from its Phase 1 proof-of-concept clinical trial of DC-806, an oral small molecule antagonist of the pro-inflammatory cytokine IL-17, will be presented in a late-breaking oral session at the 2023 American Academy of Dermatology (AAD) Annual Meeting, taking place from March 17-21 in New Orleans, LA.

• DICE Therapeutics to Participate at Upcoming Investor Conferences - February 08, 2023

  2/8/2023

  DICE Therapeutics, Inc., a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, announced management will participate at the following investor conferences.

• DICE Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

  1/4/2023

  DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced management will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023 at 12:00 p.m. PST / 3:00 p.m. EST.

• DICE Therapeutics Reports Third Quarter 2022 Financial Results and Recent Highlights

  11/9/2022

  DICE Therapeutics, Inc. (Nasdaq: DICE) today reported financial results and business highlights for the third quarter ended September 30, 2022.

• DICE Therapeutics to Present at Upcoming November 2022 Investor Conferences

  11/3/2022

  DICE Therapeutics, Inc. announced that management will present at the following investor conferences.

• DICE Therapeutics Reports Second Quarter 2022 Financial Results and Recent Highlights

  8/11/2022

  DICE Therapeutics, Inc., a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, reported financial results and business highlights for the second quarter ended June 30, 2022.

• DICE Therapeutics Announces Completion of Enrollment in Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for the Treatment of Psoriasis

  7/21/2022

  DICE Therapeutics, Inc. (Nasdaq: DICE), today announced the completion of enrollment in the Company’s Phase 1 clinical trial of DC-806 in healthy volunteers and psoriasis patients.

• DICE Therapeutics to Present at the 2022 Jefferies Healthcare Conference

  6/1/2022

  DICE Therapeutics, Inc. announced that management will present at the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 2:30 p.m. ET.

• DICE Therapeutics Reports First Quarter 2022 Financial Results and Recent Highlights

  5/12/2022

  DICE Therapeutics, Inc. reported financial results and business highlights for the first quarter ended March 31, 2022.

• DICE Therapeutics to Present at the BofA Securities 2022 Healthcare Conference

  5/3/2022

  DICE Therapeutics, Inc. today announced that management will present at the Bank of America Securities 2022 Healthcare Conference on Wednesday, May 11, 2022 at 1:20 p.m. PT / 4:20 p.m. ET.

• DICE Therapeutics Expands Management Team and Board of Directors

  3/28/2022

  DICE Therapeutics, Inc., a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, announced the appointment of Mary Riley as general counsel and the additions of Lisa Bowers and Mittie Doyle, M.D., FACR, to DICE’s board of directors.

• 

  Money on the Move: August 18 – 24

  8/25/2021

  The current continues as investment dollars flow into the life sciences. Here’s an overview who is catching the drift this week.

• DiCE Molecules Announces $60 Million Series C-1 Financing

  8/24/2021

  DiCE Molecules today announced the completion of its $60 million Series C-1 financing.

• 

  Money on the Move: Companies Rake in Cash During Week of JPM2021

  1/15/2021

  Biopharma companies raking in the cash with investment rounds and IPO announcements.

• DiCE Molecules Announces $80 Million Series C Financing

  1/8/2021

  Jake Simson, Ph.D., joins Board of Directors Financing proceeds will support the progression of the Company’s first-in-class, oral IL-17 antagonist into clinical trials and advancement of its PPI antagonist pipeline

• 

  Bay Area Biotech Forges Multi-Year Research Deal with Genentech

  12/19/2017

  A little less than two years after tying up a multi-billion deal with Sanofi, DiCE Molecules scored another collaborative deal.